VCG
VNDA icon

Vantage Consulting Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Vantage Consulting Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,724
Closed -$23K – 1534
2020
Q4 		$23K Buy
+1,724
New +$20.8K ﹤0.01% 823

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Vantage Consulting Group's VNDA Position: Q1 2021 in Review

Vantage Consulting Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2021, closing a stake of 1,724 shares — an estimated $23K sold.

Vantage Consulting Group first reported a position in VNDA in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 189 funds tracked by Wall St. Rank hold VNDA as of Q1 2021.

  • Vantage Consulting Group reported no remaining Vanda Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 1,724 Vanda Pharmaceuticals shares in Q1 2021, an estimated $23K.
  • Vantage Consulting Group first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Vanda Pharmaceuticals position peaked at $23K in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.